Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Neonatal Abstinence Syndrome Differential Diagnoses

  • Author: Ashraf H Hamdan, MD, MBBCh, MSc, MRCP; Chief Editor: Ted Rosenkrantz, MD  more...
 
Updated: Jan 02, 2016
 
 

Diagnostic Considerations

Important considerations

Many state laws and policies have been established in an attempt to prevent and/or address prenatal substance use. Existent laws address the testing, reporting, prosecution, and receipt of welfare benefits for pregnant women who use drugs.

Historically, substance abuse testing and reporting laws differ among states, as in the following examples:

  • The Guttmacher Institute reported that 4 states (Iowa, Kentucky, Minnesota, and North Dakota) require health care professionals to test for prenatal drug exposure when prenatal drug abuse is suspected, and 14 states (Alaska, Arizona, Illinois, Iowa, Louisiana, Massachusetts, Michigan, Minnesota, Montana, North Dakota, Oklahoma, Rhode Island, Utah, and Virginia) require reporting women to child protective services (CPS) for prenatal substance use. However, a recent federal law (No: 108-36) attempts to create a uniform state response to prenatal substance abuse.
  • The 2003 reauthorization of the federal Child Abuse Prevention and Treatment Act (CAPTA) requires states receiving CAPTA grants to develop a plan for medical workers to notify CPS of infants identified at birth as affected by prenatal drug exposure. The law states that this referral, in and of itself, is not grounds for a child abuse and/or neglect determination and cannot be used for criminal prosecution. Rather, it is intended to provide a safety screening and to link the mother to voluntary community services. The law also requires that CPS develop a safe plan for infants in this situation. [35]

Each physician should be familiar with his state law regarding screening and reporting of prenatal substance abuse and neonatal exposure to substances in utero.

The medicolegal implications of screening the infant who has been exposed to drugs for the purpose of providing clinical care are complex. Screening creates a conflict between maternal, fetal, and neonatal interests. Although the state courts have granted unborn children some rights in other contexts, any attempt to grant unborn children greater protection against actions taken by their mothers during pregnancy is subject to strict scrutiny. Screening neonates for illicit drugs without maternal consent is not recommended. In addition, performing these tests without maternal approval may be illegal in certain areas.

Evidence of maternal substance abuse should alert the infant's medical caretaker that the mother may have medical, psychological, or behavioral problems that could have an impact on the infant's long-term health and welfare. Testing the mother, infant, or both, with informed consent, is useful in some clinical situations, even when drug use is not suspected. Some infants may be ill served if the physician relies solely on urine toxicology testing for screening. These test findings may be negative if drugs were used early in pregnancy or during the immediate 48 hours prior to delivery. Results also depend on laboratory variability.

Special concerns

Infants exposed in-utero to drugs have a higher than expected risk of subsequent abuse compared with children in the general population.[36]

Women who abuse substances face multiple stressors, including poverty, mental illness, and past and present physical, emotional, and sexual abuse. In turn, their children must cope with the consequences of living in a home environment where their developmental needs may not be met, and where they are at risk of out-of-home placement.

Prenatal maternal alcohol and drug use predicted child maltreatment and postnatal exposure to substances, as well as increased risk for maternal involvement with a substance-abusing partner.[37]

Other problems to be considered

Hyperviscosity and intracranial hemorrhage should also be considered. Drug withdrawal should be considered as a diagnosis in infants in whom compatible signs develop. Physicians should be aware of other potential diagnoses that should be evaluated and treated, if confirmed.

Infants with signs and symptoms of neonatal abstinence syndrome (NAS) may have other conditions that result in abnormal behavior. The nonspecific nature of the clinical features of neonatal abstinence syndrome mean that some drug-exposed infants may have exaggerated scores when they are hungry or may have other conditions such as neonatal sepsis, hypoglycemia, hypocalcemia, hyperthyroidism, or subarachnoid hemorrhage. On the other hand, congenital hypothyroidism has been reported to mask the symptoms of neonatal abstinence syndrome. For that reason, assess the infant and consider whether symptoms are solely due to neonatal abstinence syndrome and whether other investigations are warranted.

Differential Diagnoses

 
 
Contributor Information and Disclosures
Author

Ashraf H Hamdan, MD, MBBCh, MSc, MRCP Clinical Associate Professor of Pediatrics, Vanderbilt University Medical Center; Neonatologist, Pediatrix Medical Group of Nashville

Ashraf H Hamdan, MD, MBBCh, MSc, MRCP is a member of the following medical societies: American Academy of Pediatrics

Disclosure: Nothing to disclose.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Brian S Carter, MD, FAAP Professor of Pediatrics, University of Missouri-Kansas City School of Medicine; Attending Physician, Division of Neonatology, Children's Mercy Hospital and Clinics; Faculty, Children's Mercy Bioethics Center

Brian S Carter, MD, FAAP is a member of the following medical societies: Alpha Omega Alpha, American Academy of Hospice and Palliative Medicine, American Academy of Pediatrics, American Pediatric Society, American Society for Bioethics and Humanities, American Society of Law, Medicine & Ethics, Society for Pediatric Research, National Hospice and Palliative Care Organization

Disclosure: Nothing to disclose.

Chief Editor

Ted Rosenkrantz, MD Professor, Departments of Pediatrics and Obstetrics/Gynecology, Division of Neonatal-Perinatal Medicine, University of Connecticut School of Medicine

Ted Rosenkrantz, MD is a member of the following medical societies: American Academy of Pediatrics, American Pediatric Society, Eastern Society for Pediatric Research, American Medical Association, Connecticut State Medical Society, Society for Pediatric Research

Disclosure: Nothing to disclose.

Additional Contributors

Scott S MacGilvray, MD Clinical Professor, Department of Pediatrics, Division of Neonatology, The Brody School of Medicine at East Carolina University

Scott S MacGilvray, MD is a member of the following medical societies: American Academy of Pediatrics

Disclosure: Nothing to disclose.

Acknowledgements

The authors and editors of Medscape Drugs & Diseases, gratefully acknowledge the contributions of previous authors Jaques Belik, MD, and Judy Hawes, RN, MN, to the writing and development of this article.

References
  1. Stover MW, Davis JM. Opioids in pregnancy and neonatal abstinence syndrome. Semin Perinatol. 2015 Nov. 39 (7):561-5. [Medline].

  2. Chana S, Anand K. Can we use methadone for Analgesia in neonates?. Arch Dis Child Fetal Neonatal Ed. 2001. 85:79-81. [Medline]. [Full Text].

  3. Franck LS, Vilardi J, Durand D, Powers R. Opioid withdrawal in neonates after continuous infusions of morphine or fentanyl during extracorporeal membrane oxygenation. Am J Crit Care. 1998 Sep. 7(5):364-9. [Medline].

  4. Substance Abuse and Mental Health Services Administration Office of Applied Studies. 2003 National Survey on Drug Use & Health: Results. US Department of Health and Human Services. Available at http://www.drugabusestatistics.samhsa.gov/NHSDA/2k3NSDUH/2k3results.htm. Accessed: December, 2007.

  5. Patrick SW, Schumacher RE, Benneyworth BD, Krans EE, McAllister JM, Davis MM. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. JAMA. 2012 May 9. 307(18):1934-40. [Medline].

  6. Hytinantti T, Kahila H, Renlund M, Jarvenpaa AL, Halmesmaki E, Kivitie-Kallio S. Neonatal outcome of 58 infants exposed to maternal buprenorphine in utero. Acta Paediatr. 2008 Aug. 97(8):1040-4. [Medline].

  7. Lim S, Prasad MR, Samuels P, Gardner DK, Cordero L. High-dose methadone in pregnant women and its effect on duration of neonatal abstinence syndrome. Am J Obstet Gynecol. 2009 Jan. 200(1):70.e1-5. [Medline].

  8. Dryden C, Young D, Hepburn M, Mactier H. Maternal methadone use in pregnancy: factors associated with the development of neonatal abstinence syndrome and implications for healthcare resources. BJOG. 2009 Apr. 116(5):665-71. [Medline].

  9. Wouldes TA, Woodward LJ. Maternal methadone dose during pregnancy and infant clinical outcome. Neurotoxicol Teratol. 2010 May-Jun. 32(3):406-13. [Medline].

  10. BJ Cleary, M Eogan, MP O’Connell, T Fahey, PJ Gallagher, T Clarke, et al. Methadone and Perinatal Outcomes – a Prospective Cohort Study. Addiction. [Medline].

  11. Minozzi S, Amato L, Bellisario C, Ferri M, Davoli M. Maintenance agonist treatments for opiate-dependent pregnant women. Cochrane Database Syst Rev. 2013. 12:CD006318. [Medline].

  12. Buprenorphine treatment in pregnancy: less distress to babies. December 9, 2010. Available at http://www.nih.gov/news/health/dec2010/nida-09.htm.

  13. Jones HE, Dengler E, Garrison A, O'Grady KE, Seashore C, Horton E. Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. Drug Alcohol Depend. 2014 Jan 1. 134:414-7. [Medline].

  14. Kandall SR. Treatment strategies for drug-exposed neonates. Clin Perinatol. 1999 Mar. 26(1):231-43. [Medline].

  15. Law KL, Stroud LR, LaGasse LL, et al. Smoking during pregnancy and newborn neurobehavior. Pediatrics. 2003 Jun. 111(6 Pt 1):1318-23. [Medline]. [Full Text].

  16. Haddad PM, Pal BR, Clarke P, Wieck A, Sridhiran S. Neonatal symptoms following maternal paroxetine treatment: serotonin toxicity or paroxetine discontinuation syndrome?. J Psychopharmacol. 2005 Sep. 19(5):554-7. [Medline].

  17. Bence C, Bonord A, Rebillard C, et al. Neonatal abstinence syndrome following tianeptine dependence during pregnancy. Pediatrics. 2015 Dec 11. [Medline].

  18. Anand KJ, Campbell-Yeo M. Consequences of prenatal opioid use for newborns. Acta Paediatr. 2015 Nov. 104 (11):1066-9. [Medline].

  19. Substance Abuse and Mental Health Services Administration. Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings. US Department of Health and Human Services. September 2013. Available at http://www.samhsa.gov/data/NSDUH/2012SummNatFindDetTables/NationalFindings/NSDUHresults2012.htm#ch2.6.

  20. Trends in Substances of Abuse among Pregnant Women and Women of Childbearing Age in Treatment. July 2013. Available at http://www.samhsa.gov/data/spotlight/spot110-trends-pregnant-women-2013.pdf.

  21. SAMHSA. Substance Use among Women During Pregnancy and Following Childbirth. Substance Abuse and Mental Health Services Administration. May 21, 2009. Available at http://www.oas.samhsa.gov/2k9/135/PregWoSubUse.htm.

  22. Cairns PA. Drug misuse: Conception into childhood. Current Paediatrics. 2001 December. 11(6):475-9.

  23. Prentice S. Substance misuse in pregnancy. Obstetrics, Gynaecology & Reproductive Med. 2007 September. 17:272-7.

  24. Gyarmathy VA, Giraudon I, Hedrich D, Montanari L, Guarita B, Wiessing L. Drug use and pregnancy - challenges for public health. Euro Surveill. 2009 Mar 5. 14(9):33-6. [Medline]. [Full Text].

  25. Licit and Illicit Drug Use during Pregnancy: Maternal, Neonatal and Early Childhood Consequences. 2013. Available at http://www.ccsa.ca/2013%20CCSA%20Documents/CCSA-Drug-Use-during-Pregnancy-Summary-2013-en.pdf.

  26. Substance Use During Pregnancy: 2002 and 2003 Update. National survey on drug use and health. June 2, 2005. Available at http://www.oas.samhsa.gov/2k5/pregnancy/pregnancy.htm.

  27. Lester BM, ElSohly M, Wright LL, Smeriglio VL, Verter J, Bauer CR. The Maternal Lifestyle Study: drug use by meconium toxicology and maternal self-report. Pediatrics. 2001 Feb. 107(2):309-17. [Medline].

  28. [Guideline] American Academy of Pediatrics Committee on Substance Abuse. Drug-exposed infants. Pediatr. 1995 Aug. 96(2 Pt 1):364-7. [Medline].

  29. Doberczak TM, Kandall SR, Wilets I. Neonatal opiate abstinence syndrome in term and preterm infants. J Pediatr. 1991 Jun. 118(6):933-7. [Medline].

  30. Liu AJ, Jones MP, Murray H, Cook CM, Nanan R. Perinatal risk factors for the neonatal abstinence syndrome in infants born to women on methadone maintenance therapy. Aust N Z J Obstet Gynaecol. 2010 Jun. 50(3):253-8. [Medline].

  31. [Guideline] Hudak ML, Tan RC. Neonatal Drug Withdrawal. Pediatrics. January 2012. 129(2):e540-560. [Full Text].

  32. Finnegan LP. Neonatal abstinence syndrome: assessment and pharmacolotherapy. Neonatal therapy: An update. New York, NY: Excerpta Medica; 1986. 122-46.

  33. Ostrea EM, Ostrea AR, Simpson PM. Mortality within the first 2 years in infants exposed to cocaine, opiate, or cannabinoid during gestation. Pediatrics. 1997 Jul. 100(1):79-83. [Medline]. [Full Text].

  34. Lester BM, Tronick EZ. History and description of the Neonatal Intensive Care Unit Network Neurobehavioral Scale. Pediatrics. 2004 Mar. 113(3 Pt 2):634-40. [Medline].

  35. Maternal Resource Center. Prenatal Substance Exposure. April 2008. [Full Text].

  36. Jaudes PK, Ekwo E, Van Voorhis J. Association of drug abuse and child abuse. Child Abuse Negl. 1995 Sep. 19(9):1065-75. [Medline].

  37. Smith DK, Johnson AB, Pears KC, Fisher PA, DeGarmo DS. Child maltreatment and foster care: unpacking the effects of prenatal and postnatal parental substance use. Child Maltreat. 2007 May. 12(2):150-60. [Medline].

  38. Chasnoff IJ. Prenatal substance exposure: maternal screening and neonatal identification and management. Neoreviews. 2003. 4(9):e228-e235.

  39. Gray T, Huestis M. Bioanalytical procedures for monitoring in utero drug exposure. Anal Bioanal Chem. 2007 Aug. 388(7):1455-65. [Medline].

  40. van Huis M, van Kempen AA, Peelen M, Timmers M, Boer K, Smit BJ. Brain ultrasonography findings in neonates with exposure to cocaine during pregnancy. Pediatr Radiol. 2009 Mar. 39(3):232-8. [Medline].

  41. Kassima Z, Greenough A. Neonatal abstinence syndrome: Identification and management. Current Paediatrics. 2006 June. 16:172-5.

  42. Lainwala S, Brown ER, Weinschenk NP, Blackwell MT, Hagadorn JI. A retrospective study of length of hospital stay in infants treated for neonatal abstinence syndrome with methadone versus oral morphine preparations. Adv Neonatal Care. 2005 Oct. 5(5):265-72. [Medline].

  43. Kraft WK, Gibson E, Dysart K, et al. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics. 2008 Sep. 122(3):e601-7. [Medline]. [Full Text].

  44. Young ME, Hager SJ, Spurlock D Jr. Retrospective chart review comparing morphine and methadone in neonates treated for neonatal abstinence syndrome. Am J Health Syst Pharm. 2015 Dec 1. 72 (23 suppl 3):S162-7. [Medline].

  45. Hall ES, Isemann BT, Wexelblatt SL, et al. A cohort comparison of buprenorphine versus methadone treatment for neonatal abstinence syndrome. J Pediatr. 2015 Dec 15. [Medline].

  46. Hall ES, Wexelblatt SL, Crowley M, Grow JL, Jasin LR, Klebanoff MA, et al. A multicenter cohort study of treatments and hospital outcomes in neonatal abstinence syndrome. Pediatrics. 2014 Aug. 134(2):e527-34. [Medline].

  47. Pullen L. Neonatal Abstinence Syndrome: Stringent Weaning Protocol Best. Available at http://www.medscape.com/viewarticle/829115. Accessed: August 4, 2014.

  48. Saiki T, Lee S, Hannam S, Greenough A. Neonatal abstinence syndrome--postnatal ward versus neonatal unit management. Eur J Pediatr. 2010 Jan. 169(1):95-8. [Medline].

  49. Backes CH, Backes CR, Gardner D, Nankervis CA, Giannone PJ, Cordero L. Neonatal abstinence syndrome: transitioning methadone-treated infants from an inpatient to an outpatient setting. J Perinatol. 2012 Jun. 32(6):425-30. [Medline].

  50. Committee on Health Care for Underserved Women and the American Society of Addiction Medicine. Opioid Abuse, Dependence, and Addiction in Pregnancy. 2012 May. 524:[Full Text].

  51. Jansson LM. ABM clinical protocol #21: Guidelines for breastfeeding and the drug-dependent woman. Breastfeed Med. 2009 Dec. 4(4):225-8. [Medline]. [Full Text].

  52. Grim K, Harrison TE, Wilder RT. Management of neonatal abstinence syndrome from opioids. Clin Perinatol. 2013 Sep. 40(3):509-24. [Medline].

  53. Agthe AG, Kim GR, Mathias KB, et al. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. Pediatrics. 2009 May. 123(5):e849-56. [Medline]. [Full Text].

  54. Sarkar S, Donn SM. Management of neonatal abstinence syndrome in neonatal intensive care units: a national survey. J Perinatol. 2006 Jan 1. 26(1):15-7. [Medline].

  55. [Guideline] American Academy of Pediatrics Committee on Drugs. Neonatal drug withdrawal. [published erratum appears in Pediatrics 1998 Sep;102(3 Pt 1):660]. Pediatrics. 1998 Jun. 101(6):1079-88. [Medline].

  56. Mazurier E, Cambonie G, Barbotte E, Grare A, Pinzani V, Picaud JC. Comparison of chlorpromazine versus morphine hydrochloride for treatment of neonatal abstinence syndrome. Acta Paediatr. 2008 Oct. 97(10):1358-61. [Medline].

  57. SAMHSA. The Drug Addiction Treatment Act of 2000 (DATA 2000). DHHS. 2000. Available at http://buprenorphine.samhsa.gov/.

  58. Kraft WK, Gibson E, Dysart K, Damle VS, Larusso JL, Greenspan JS. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics. 2008 Sep. 122(3):e601-7. [Medline]. [Full Text].

  59. [Guideline] Jansson LM, Choo R, Velez ML, Harrow C, Schroeder JR, Shakleya DM. Methadone maintenance and breastfeeding in the neonatal period. Pediatrics. 2008 Jan. 121(1):106-14. [Medline].

  60. [Guideline] AAP. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001 Sep. 108(3):776-89. [Medline].

  61. Anthony BE, Bryan BL. Neonatal Abstinence Syndrome. NeoReviews. 2009. 10(5):e222.

  62. Hale TW. Pharmacology review: drug therapy and breastfeeding: antidepressants, antipsychotics, antimanics, and sedatives. NeoReviews. May 2004. e451 -e456.

  63. Irner TB, Teasdale TW, Nielsen T, Vedal S, Olofsson M. Substance use during pregnancy and postnatal outcomes. J Addict Dis. 2012 Jan. 31(1):19-28. [Medline].

  64. Gray KA, Day NL, Leech S, Richardson GA. Prenatal marijuana exposure: effect on child depressive symptoms at ten years of age. Neurotoxicol Teratol. 2005 May-Jun. 27(3):439-48. [Medline].

  65. Goldschmidt L, Day NL, Richardson GA. Effects of prenatal marijuana exposure on child behavior problems at age 10. Neurotoxicol Teratol. 2000 May-Jun. 22(3):325-36. [Medline].

  66. American Academy of Pediatrics. Pickering LK. The Red Book: 2006 Report of the Committee on Infectious Diseases. 27th. 2006.

  67. [Guideline] American Academy of Pediatrics Committee on Fetus and Newborn. The initiation or withdrawal of treatment for high-risk newborns. Pediatrics. 1995 Aug. 96(2 Pt 1):362-3. [Medline].

  68. Bahwere P, Haumont D, Delange F. Congenital hypothyroidism and neonatal withdrawal syndrome. Eur J Pediatr. 1996 Nov. 155(11):937-8. [Medline].

  69. Bauer CR. Perinatal effects of prenatal drug exposure. Neonatal aspects. Clin Perinatol. 1999 Mar. 26(1):87-106. [Medline].

  70. Boukydis CF, Lester BM. The NICU Network Neurobehavioral Scale. Clinical use with drug exposed infants and their mothers. Clin Perinatol. 1999 Mar. 26(1):213-30. [Medline].

  71. Buchi KF. The drug-exposed infant in the well-baby nursery. Clin Perinatol. 1998 Jun. 25(2):335-50. [Medline].

  72. Chasnoff IJ, Bussey ME, Savich R, Stack CM. Perinatal cerebral infarction and maternal cocaine use. J Pediatr. 1986 Mar. 108(3):456-9. [Medline].

  73. Connolly WB Jr, Marshall AB. Drug addiction, pregnancy, and childbirth: legal issues for the medical and social services communities. Clin Perinatol. 1991 Mar. 18(1):147-86. [Medline].

  74. Frank L. Assessment and management of opioid withdrawal in ill neonates. Neonatal Network. March. 14:39-48. [Medline].

  75. Heier LA, Carpanzano CR, Mast J, Brill PW, Winchester P, Deck MD. Maternal cocaine abuse: the spectrum of radiologic abnormalities in the neonatal CNS. AJNR Am J Neuroradiol. 1991 Sep-Oct. 12(5):951-6. [Medline].

  76. Johnson K, Gerada C, Greenough A. Treatment of neonatal abstinence syndrome. Arch Dis Child Fetal Neonatal Ed. 2003 Jan. 88(1):F2-5. [Medline].

  77. Jones HE, Heil SH, Baewert A, Arria AM, Kaltenbach K, Martin PR. Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review. Addiction. 2012 Nov. 107 Suppl 1:5-27. [Medline].

  78. Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med. 2004 Apr. 158(4):312-6. [Medline]. [Full Text].

  79. Kaltenbach K, Berghella V, Finnegan L. Opioid dependence during pregnancy. Effects and management. Obstet Gynecol Clin North Am. 1998 Mar. 25(1):139-51. [Medline].

  80. Kandall RS. Improving Treatment for Drug-Exposed Infants Treatment Improvement Protocol (TIP) Series 5. Available at http://ncadi.samhsa.gov/govpubs/bkd110/default.aspx. Accessed: February, 14 2010.

  81. Kuschel C. Managing drug withdrawal in the newborn infant. Semin Fetal Neonatal Med. 2007 Apr. 12(2):127-33. [Medline].

  82. McKim EM. Caffeine and its effects on pregnancy and the neonate. J Nurse Midwifery. 1991 Jul-Aug. 36(4):226-31. [Medline].

  83. Moses-Kolko EL, Bogen D, Perel J, Bregar A, Uhl K, Levin B. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA. 2005 May 18. 293(19):2372-83. [Medline].

  84. Oei J, Lui K. Management of the newborn infant affected by maternal opiates and other drugs of dependency. J Paediatr Child Health. 2007 Jan-Feb. 43(1-2):9-18. [Medline].

  85. Pierog S, Chandavasu O, Wexler I. Withdrawal symptoms in infants with the fetal alcohol syndrome. J Pediatr. 1977 Apr. 90(4):630-3. [Medline].

  86. Pritham UA. Breastfeeding promotion for management of neonatal abstinence syndrome. J Obstet Gynecol Neonatal Nurs. 2013 Sep-Oct. 42(5):517-26. [Medline].

  87. SAMHSA. Special issues during pregnancy. DHHS. May 21, 2009. Available at http://www.ncsacw.samhsa.gov/files/Special_Issues_Pregnancy_Factsheets.pdf.

  88. Sanz EJ, De-las-Cuevas C, Kiuru A, et al. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet. 2005 Feb 5-11. 365(9458):482-7. [Medline].

  89. Ter Horst PG, Jansman FG, van Lingen RA, Smit JP, de Jong-van den Berg LT, Brouwers JR. Pharmacological aspects of neonatal antidepressant withdrawal. Obstet Gynecol Surv. 2008 Apr. 63(4):267-79. [Medline].

  90. Theis JG, Selby P, Ikizler Y, Koren G. Current management of the neonatal abstinence syndrome: a critical analysis of the evidence. Biol Neonate. 1997. 71(6):345-56. [Medline].

  91. Umans JG, Szeto HH. Precipitated opiate abstinence in utero. Am J Obstet Gynecol. 1985 Feb 15. 151(4):441-4. [Medline].

  92. Vance JC, Chant DC, Tudehope DI, et al. Infants born to narcotic dependent mothers: physical growth patterns in the first 12 months of life. J Paediatr Child Health. 1997 Dec. 33(6):504-8. [Medline].

  93. Wagner CL, Katikaneni LD, Cox TH, Ryan RM. The impact of prenatal drug exposure on the neonate. Obstet Gynecol Clin North Am. 1998 Mar. 25(1):169-94. [Medline].

  94. Young T E, Mangum B. CNS Drugs. Thomson Reuters clinical editorial staff. Neofax: A manual of drugs used in neonatal care. 22nd ed. Montvale, New Jersey: Thomson Reuters healthcare; 2009. 187-214.

  95. Zeskind PS, Stephens LE. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics. 2004 Feb. 113(2):368-75. [Medline].

 
Previous
Next
 
Neonatal abstinence syndrome scoring form.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.